We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Anticancer Therapies – Products

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial content piece image
Product News

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial

Avacta Group plc is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.
Investigating Synthetic Immune Recruitment by Proximity Inducing Molecules content piece image
Whitepaper

Investigating Synthetic Immune Recruitment by Proximity Inducing Molecules

Download this whitepaper to learn how Octet® Bio-Layer Interferometry (BLI) assays can accelerate the advancement of lead compounds to in vivo validation studies.
Waters Sets New Standard in High Resolution Mass Spectrometry  content piece image
Product News

Waters Sets New Standard in High Resolution Mass Spectrometry

Waters Corporation has introduced the Waters™ SELECT SERIES™ MRT, a high-resolution mass spectrometer that combines Multi Reflecting Time-of-Flight (MRT) technology with both enhanced DESI and new MALDI imaging sources.
Beckman Coulter Launches Access AMH Advanced content piece image
Product News

Beckman Coulter Launches Access AMH Advanced

The new Access Anti-Müllerian hormone (AMH) Advanced is the only test on the market to provide validated cut-offs for the assessment of ovarian reserve and ovarian response as an aid for women undergoing in vitro fertilisation (IVF) .
GammaDelta Therapeutics Receives FDA Clearance For Novel Cell Cancer Therapy  content piece image
Product News

GammaDelta Therapeutics Receives FDA Clearance For Novel Cell Cancer Therapy

GammaDelta Therapeutics has announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for the Company’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy,
Adaptate Biotherapeutics Raises $18 million in Series A2 Funding  content piece image
Product News

Adaptate Biotherapeutics Raises $18 million in Series A2 Funding

Adaptate Biotherapeutics has announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited have together made a further equity investment of $18 million.
Pathios Therapeutics Awarded Grant To Accelerate Cancer Immunotherapy Programme content piece image
Product News

Pathios Therapeutics Awarded Grant To Accelerate Cancer Immunotherapy Programme

Pathios Therapeutics Limited today announced that it has been awarded £350K (approximately US$475K) in the form of a Smart Grant from Innovate UK, the UK Government’s innovation agency, to accelerate their cancer immunotherapy program targeting the innate immune checkpoint, GPR65.
Dotmatics Announces Licensing Agreement for Informatics Software With Compugen content piece image
Product News

Dotmatics Announces Licensing Agreement for Informatics Software With Compugen

Dotmatics Ltd, has announced that it has entered a licensing agreement with Compugen. The multi-year agreement will provide Compugen scientists based at the Company’s R&D facility in Israel with a single information management platform.
Vivan Therapeutics Joins Repositive Cancer Model Network content piece image
Product News

Vivan Therapeutics Joins Repositive Cancer Model Network

Repositive has announced that Vivan Therapeutics will be the next company to join its global network of cancer model partners. With this new partnership, Repositive is expanding its personalized medicine capabilities to support more biopharma customers in their oncology drug development programs.
Patient-Derived Human Primary Cancer Cells content piece image
Product News

Patient-Derived Human Primary Cancer Cells

AMSBIO has expanded its range of primary human cancer cells sourced from a wide variety of tissue types that allow the study of cancer in a more in vivo like fashion.
Advertisement